Fig. 5

The comparison of growth data and tumor metabolomics between PDXG1, PDXG3, PDXG1CH and PDXG3CH. Figure 5A. The tumor volume line graph of PDXG1, PDXG3, PDXG1CH and PDXG3CH. Figure 5B. The photograph of PDXG1CH and PDXG3CH tumor after receiving Albumin-bound paclitaxel plus gemcitabine (AG) treatment. All mice in PDXG1CH and PDXG3CH had intraperitoneal injections of AG every 7 days and sacrificed after 4 rounds of AG treatment to collect tumor samples. Figure 5C The changes in tumor volume of PDXG1CH and PDXG3CH before and after chemotherapy. Figure 5D The representative H&E pathological images of AG-resistant and AG-response tumor in corresponding PDXG1, PDXG3, PDXG1CH and PDXG3CH groups. Compare with AG-resistant tumor, the AG-response tumor had numerous fibrous stroma and there was significant lymphocyte infiltration after receiving treatment. Meanwhile, only a small amount of residual cancer cells remained (Yellow arrow). Figure 5E. The PCA score plot of metabolomic data of tumor samples from PDXG1, PDXG3, PDXG1CH and PDXG3CH. Figure 5F-P. The histogram of the relative concentration of metabolites associated with glycolysis and amino acids in PDXG1, PDXG1CH, PDXG3 and PDXG3CH.